EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

Timing of Sodium–Glucose Cotransporter 2 Inhibitor Initiation and Post-Discharge Outcomes in Acute Heart Failure with Diabetes: A Population-Based Cohort Study

Che-Yuan Wu, Baiju R Shah, Abhinav Sharma, Yiru Sheng, Peter P Liu, Alexander Kopp, Refik Saskin, Jodi D Edwards, Walter Swardfager iD

European Journal of Heart Failure · 2025

DOI: 10.1002/ejhf.3464 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift European Journal of Heart Failure, 2025. Verfasst von Che-Yuan Wu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Heart Failure, Diabetes Mellitus, Type 2, Patient Discharge. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CIHR, Heart and Stroke Foundation of Canada, Heart-Brain Connection BHRIITE IMPACT Award, Canada First Research Excellence Fund, Heart-Brain Connection BHRIITE IMPACT Award.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Results from randomized trials suggest benefit of sodium–glucose cotransporter 2 (SGLT2) inhibitor initiation in clinically stable acute heart failure. We aim to examine the real-world effectiveness of early versus delayed post-discharge SGLT2 inhibitor initiation in people with acute heart failure and type 2 diabetes. Methods and results Using linkable administrative databases in Ontario, Canada, individuals aged 66 years or older with type 2 diabetes who were discharged to the community from acute care hospitals for heart failure between 1 July 2016 and 31 March 2020 were included in this retrospective, population-based cohort study. The primary outcome was hospitalization for heart failure (HHF) or cardiovascular mortality as a composite. Follow-up started from discharge for maximum 1 year. We compared outcomes between post-discharge SGLT2 inhibitor initiation within 3 days, 4–90 days, or 91–180 days, versus delayed initiation for at least 180 days. The ‘clone-censor-weight’ approach with a target trial emulation framework was used to address time-related biases. There were 9641 eligible individuals. After cloning and artificial censoring, there were 38 564 clones, 12 439 person-years, and 7584 events. Compared to delayed initiation for at least 180 days, initiation within 3 days post-discharge was associated with a lower 1-year risk of HHF or cardiovascular mortality (risk ratio [RR] 0.65, 95% confidence interval [CI] 0.45–0.83), while initiation 4–90 days (RR 0.83, 95% CI 0.72–0.93) or 91–180 days (RR 0.89, 95% CI 0.79–0.97) showed smaller risk reduction.

Conclusion

Real-world evidence supports early SGLT2 inhibitor initiation to reduce HHF or cardiovascular mortality in acute heart failure and type 2 diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsHeart FailureDiabetes Mellitus, Type 2Patient DischargeHumansFemaleMaleAgedRetrospective StudiesOntarioAcute DiseaseTime FactorsHospitalizationFollow-Up StudiesTreatment Outcome

Stichwörter der Autor:innen

Acute heart failureDiabetesPharmacoepidemiologySGLT2 inhibitor

Substanzen

Sodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.
  • Dr. Sandra Black Centre for Brain Resilience and Recovery, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, ON, Canada.
  • ICES, Toronto, ON, Canada.
  • Division of Endocrinology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
  • Department of Medicine, University of Toronto, Toronto, ON, Canada.
  • Division of Cardiology, McGill University Health Centre, McGill University, Montreal, QC, Canada.

ORCID-Profile: Walter Swardfager

Förderung

  • CIHR
  • Heart and Stroke Foundation of Canada, Heart-Brain Connection BHRIITE IMPACT Award
  • Canada First Research Excellence Fund, Heart-Brain Connection BHRIITE IMPACT Award
  • Temerty Faculty of Medicine, University of Toronto, Novo Nordisk Research Chair in Equitable Care of Diabetes and Related Conditions
  • Canada Research Chairs
  • Ministry of Colleges and Universities
  • Canadian Institutes of Health Research
  • Heart and Stroke Foundation of Canada

Zitieren

APA

Wu, C. Y., Shah, B. R., Sharma, A., Sheng, Y., Liu, P. P., Kopp, A., Saskin, R., Edwards, J. D., & Swardfager, W. (2025). Timing of Sodium–Glucose Cotransporter 2 Inhibitor Initiation and Post-Discharge Outcomes in Acute Heart Failure with Diabetes: A Population-Based Cohort Study. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.3464

Vancouver

Wu CY, Shah BR, Sharma A, Sheng Y, Liu PP, Kopp A, et al. Timing of Sodium–Glucose Cotransporter 2 Inhibitor Initiation and Post-Discharge Outcomes in Acute Heart Failure with Diabetes: A Population-Based Cohort Study. European Journal of Heart Failure. 2025. doi:10.1002/ejhf.3464

BibTeX
@article{Wu2025,
  author = {Wu, Che-Yuan and Shah, Baiju R and Sharma, Abhinav and Sheng, Yiru and Liu, Peter P and Kopp, Alexander and Saskin, Refik and Edwards, Jodi D and Swardfager, Walter},
  title = {Timing of Sodium–Glucose Cotransporter 2 Inhibitor Initiation and Post-Discharge Outcomes in Acute Heart Failure with Diabetes: A Population-Based Cohort Study},
  journal = {European Journal of Heart Failure},
  year = {2025},
  doi = {10.1002/ejhf.3464}
}
Kostenlos starten →